An open-label, multicenter, phase II study of ceritinib in patients with advanced ALK+ non-lung solid tumors and hematological malignancies (ASCEND-10). ascopubs.org/doi/10.1200/JC… We report the lack of ceritinib activity in recurrent GBM in this phase II basket trial.